These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27793642)

  • 1. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E
    Am J Med; 2017 Feb; 130(2):173-187. PubMed ID: 27793642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of niacin in current clinical practice.
    Sharma A; Madan N
    Minerva Med; 2019 Feb; 110(1):79-83. PubMed ID: 30334440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS
    JAMA Netw Open; 2019 Apr; 2(4):e192224. PubMed ID: 30977858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):158-66. PubMed ID: 20208032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH
    J Am Coll Cardiol; 2013 Jan; 61(4):440-446. PubMed ID: 23265337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Ponce OJ; Larrea-Mantilla L; Hemmingsen B; Serrano V; Rodriguez-Gutierrez R; Spencer-Bonilla G; Alvarez-Villalobos N; Benkhadra K; Haddad A; Gionfriddo MR; Prokop LJ; Brito JP; Murad MH
    J Clin Endocrinol Metab; 2019 May; 104(5):1585-1594. PubMed ID: 30903687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The facts behind niacin.
    Hochholzer W; Berg DD; Giugliano RP
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
    Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
    J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):9-23. PubMed ID: 25439661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrates and niacin: is there a place for them in clinical practice?
    Wierzbicki AS; Viljoen A
    Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment of hyperlipidemia in women.
    Walsh JM; Pignone M
    JAMA; 2004 May; 291(18):2243-52. PubMed ID: 15138247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of niacin on atherosclerotic cardiovascular disease.
    Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):18U-23U; discussion 39U-41U. PubMed ID: 9915658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?
    Mani P; Rohatgi A
    Curr Atheroscler Rep; 2015 Aug; 17(8):43. PubMed ID: 26048725
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.